Quality of life among pulmonary hypertension patients in Finland

Figures & data

Table 1 Patient characteristics

Patient characteristics	n (%)	Mean±SD
Age		53±16.2
Gender, female	46 (74%)
Living arrangements
• Single	28 (45%)
• With a family member	34 (55%)
Employment status
• Unemployed	3 (5%)
• Employed	17 (27%)
• On sick leave	3 (5%)
• Retired	39 (63%)
Etiology
• IPAH	25 (40%)
• APAH	16 (26%)
• CTEPH	21 (34%)
WHO FC
• I	8 (13%)
• II	28 (45%)
• III	26 (42%)
Medications
• PDE-5i	55 (89%)
• ERA	19 (31%)
• Prostanoids	12 (19%)
• CCBs	15 (24%)
• Warfarin/LMWH	46/11 (74/18%)
• Digoxin	14 (23%)
• Diuretics	31 (50%)
• Oxygen	8 (13%)
6MWT (n=59)		443 m±160
Pro-BNP (n=59)		1,105 ng/l±1,739
Right heart surface (n=59)		51 cm^2±21
TAPSE (n=59)		18 mm±6
mPAP (n=60)		49 mmHg±9
PVR (n=35)		11 WU±4
Pericardial effusion, yes	7 (11.5%)

IPAH, idiopathic pulmonary arterial hypertension; APAH, associated pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; WHO FC, World Health Organization functional class; PDE5i, phosphodiesterase type 5 inhibitors; ERA, endothelin receptor antagonists; CCBs, calcium channel blockers; LMWH, low-molecular-weight heparins; 6MWT, 6-min walking test; pro-BNP, pro-brain natriuretic peptide; TAPSE, tricuspid annular plane systolic excursion; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance.

Fig. 1 Scores for total sample. PF, physical functioning; RP, physical role functioning; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, emotional role functioning; MH, mental health; PCS, physical component score; MCS, mental component score.